The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behcet Disease and their association with thrombosis

Basit Öğe Kaydı
dc.contributor.authorDonmez, Ayhan
dc.contributor.authorAksu, Kenan
dc.contributor.authorAydin, Hakan
dc.contributor.authorKeser, Gokhan
dc.contributor.authorCagirgan, Seckin
dc.contributor.authorDoganavsargil, Eker
dc.contributor.authorTombuloglu, Murat
dc.date.accessioned2019-10-27T21:15:29Z
dc.date.available2019-10-27T21:15:29Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: To investigate the plasma levels of activated thrombin activatable fibrinolysis inhibitor (aTAFI) and thrombomodulin (TM) in Behcet disease (BD) and their relationship with thrombosis. Methods: Plasma aTAFI and TM levels were measured by ELISA in 89 patients with BD (18 having venous thrombosis) and in 86 healthy controls. Results: Compared with healthy controls, the BD group had significantly lower levels of aTAFI (13.49 +/- 8.88 mu g/ml vs. 26.76 +/- 11.57 mu g/ml, p<0.0001) and significantly higher levels of TM (3.26 +/- 1.85 ng/ml vs. 2.6 +/- 0.69 ng/ml, p=0.0003). Neither aTAFI, nor TM levels differed significantly between BD patients with and without thrombosis (p>0.05). Despite a tendency to positive correlation (r=0.37, p=0.0004) between plasma levels of aTAFI and TM in healthy controls, there was a tendency for negative correlation (r=-0.51, p<0.0001) between these two parameters in BD patients. Conclusion: The plasma aTAFI and TM levels do not seem to be related with the presence of thrombosis observed in BD. Increased plasma TM levels in BD may simply reflect endothelial cell activation and dysfunction. (C) 2010 Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipEge University Research FoundationEge University [2006-TIP-004]; Ege University Research Ethics CommitteeEge University [05/12-9]en_US
dc.description.sponsorshipThis study was supported by Ege University Research Foundation (2006-TIP-004, Ege University Research Ethics Committee Decision Number: 05/12-9; 9.3.2006).en_US
dc.identifier.doi10.1016/j.thromres.2010.05.019en_US
dc.identifier.endpage210en_US
dc.identifier.issn0049-3848
dc.identifier.issue3en_US
dc.identifier.pmid20542541en_US
dc.identifier.startpage207en_US
dc.identifier.urihttps://doi.org/10.1016/j.thromres.2010.05.019
dc.identifier.urihttps://hdl.handle.net/11454/43543
dc.identifier.volume126en_US
dc.identifier.wosWOS:000281386000009en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofThrombosis Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectActivated thrombin activatable fibrinolysis inhibitoren_US
dc.subjectBehcet diseaseen_US
dc.subjectThrombomodulinen_US
dc.subjectThrombosisen_US
dc.titleThe plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behcet Disease and their association with thrombosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu